Grindeks (GRD1R):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Grindeks (GRD1R) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C10146
◆発行会社(調査会社):GlobalData
◆発行日:2018年11月
◆ページ数:28
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:ラトビア
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Grindeks focuses on the research, development, manufacture and marketing of novel pharmaceuticals, generic products and active pharmaceutical ingredients (APIs). Its products are indicated for treating diseases in cardiovascular, central nervous system (CNS) and cancer therapeutic categories. The company provides final dosage form pharmaceutical products ranging from solid form products, solution for injections to syrups and ointments. Grindeks also provides regulatory, analytical and final dosage form contract manufacturing services to pharmaceutical companies. Through subsidiaries and representative offices, the company markets its products in the European (EU) countries, the US, Canada, Russia and other CIS countries, Japan and Vietnam. Grindeks operates subsidiary companies in Latvia, Estonia, Russia and Slovakia and is headquartered in Riga, Latvia.

Grindeks (GRD1R) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Grindeks, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Grindeks, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Grindeks, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Grindeks, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Grindeks, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Grindeks, Pharmaceuticals & Healthcare, Deal Details 10
Private Equity 10
AB.LV Private Equity Fund Acquires Stake In Grindeks From East Capital 10
Partnerships 11
Riga Stradins University to Enter into Agreement with Grindeks 11
Acquisition 12
Grindeks Completes Acquisition of HBM Pharma from Dashdirect for USD24.7 Million 12
Grindeks – Key Competitors 13
Grindeks – Key Employees 14
Grindeks – Locations And Subsidiaries 15
Head Office 15
Other Locations & Subsidiaries 15
Recent Developments 17
Financial Announcements 17
Aug 30, 2018: Grindeks: Financial results for the first six months of 2018 17
Aug 30, 2018: Turnover of Grindeks reaches 71.5 million euro in the first six months of 2018; profit – 6.7 million euro 18
May 31, 2018: On “Grindeks” results in the first three months of 2018 19
May 07, 2018: Turnover of “Grindeks” reaches 132.4 million euro in 2017; profit – 10.0 million euro 20
Feb 28, 2018: Turnover of Grindeks reaches 132.4 million euro in 2017; profit – 10.3 million euro 21
Nov 27, 2017: On Grindeks results in the first nine months of 2017 22
Aug 28, 2017: Grindeks results in the first half-year of 2017 23
May 29, 2017: On “Grindeks” results in the first three months of 2017 24
Feb 28, 2017: Grindeks Announces results in 2016 25
Corporate Communications 26
Jan 09, 2018: Juris Bundulis re-elected as the Chairman of the Board; Ph.D. Juris Hmelnickis to become a Board Member of JSC Grindeks 26
Mar 01, 2017: Grindeks Announces the Board Change 27
Appendix 28
Methodology 28
About GlobalData 28
Contact Us 28
Disclaimer 28

List of Tables
Grindeks, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Grindeks, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Grindeks, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Grindeks, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Grindeks, Deals By Therapy Area, 2012 to YTD 2018 8
Grindeks, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
AB.LV Private Equity Fund Acquires Stake In Grindeks From East Capital 10
Riga Stradins University to Enter into Agreement with Grindeks 11
Grindeks Completes Acquisition of HBM Pharma from Dashdirect for USD24.7 Million 12
Grindeks, Key Competitors 13
Grindeks, Key Employees 14
Grindeks, Subsidiaries 15

List of Figures
Grindeks, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Grindeks, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Grindeks, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Grindeks, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Grindeks, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Grindeks, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Grindeks, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Grindeks, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

★海外企業調査レポート[Grindeks (GRD1R):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Unitika Ltd (3103):企業の財務・戦略的SWOT分析
    Unitika Ltd (3103) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and th …
  • Genesis Energy, L.P.:企業の戦略・SWOT・財務分析
    Genesis Energy, L.P. - Strategy, SWOT and Corporate Finance Report Summary Genesis Energy, L.P. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings …
  • Voith Hydro Holding GmbH & Co KG:企業の戦略的SWOT分析
    Voith Hydro Holding GmbH & Co KG - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major pr …
  • Dayton Superior Corporation:企業の戦略的SWOT分析
    Dayton Superior Corporation - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major product …
  • Century Aluminum Co:企業の戦略・SWOT・財務分析
    Century Aluminum Co - Strategy, SWOT and Corporate Finance Report Summary Century Aluminum Co - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings a …
  • ThyssenKrupp AG:企業の戦略・SWOT・財務情報
    ThyssenKrupp AG - Strategy, SWOT and Corporate Finance Report Summary ThyssenKrupp AG - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpo …
  • Breakthru Beverage Group, LLC:企業の戦略・SWOT・財務情報
    Breakthru Beverage Group, LLC - Strategy, SWOT and Corporate Finance Report Summary Breakthru Beverage Group, LLC - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and …
  • SPAR Osterreichische Warenhandels AG:企業の戦略的SWOT分析
    SPAR Osterreichische Warenhandels AG - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and majo …
  • Safe Orthopaedics SA (SAFOR):企業の財務・戦略的SWOT分析
    Summary Safe Orthopaedics SA (Safe Orthopaedics) is medical device company that manufactures and markets devices for spinal surgery. The company’s products comprise implants and surgical instruments. It also offers modular cervical cages, percutaneous auto-correction screws, modular anchorage screws …
  • USV Pvt Ltd:製薬・医療:M&Aディール及び事業提携情報
    Summary USV Pvt Ltd (USV) is a healthcare company that offers pharmaceutical products. The company’s products include active pharmaceutical ingredients, biosimilars, injectables, ophthalmics, peptides and solid orals. Its biosimilars products comprise PEG-filgrastim, teriparatide, somatropin, filgra …
  • Yokogawa Electric Corporation:戦略・SWOT・企業財務分析
    Yokogawa Electric Corporation - Strategy, SWOT and Corporate Finance Report Summary Yokogawa Electric Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and …
  • Ovintiv Canada ULC:企業の戦略的SWOT分析
    Ovintiv Canada ULC - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and ser …
  • Shuwen Biotech Co Ltd:医療機器:M&Aディール及び事業提携情報
    Summary Shuwen Biotech Co Ltd (Shuwen Biotech) is a medical equipment company. The company develops diagnostic products and services for disease prevention, diagnosis and personalized medicine. It offers in-vitro diagnostic (IVD) kits for oncology and pregnancy-related conditions. Shuwen Biotech dev …
  • Southwestern Energy Co (SWN):企業の財務・戦略的SWOT分析
    Southwestern Energy Co (SWN) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknes …
  • Harvard Stem Cell Institute-製薬・医療分野:企業M&A・提携分析
    Summary Harvard Stem Cell Institute (HSCI), a subsidiary of Harvard University is a healthcare institute that conducts research on advance stem cell science using stem cell biology to develop new treatments and cures for disease. The institute provides research programs such as disease programs, cor …
  • NovImmune SA-製薬・医療分野:企業M&A・提携分析
    Summary NovImmune SA (NovImmune) is a biopharmaceutical company that discovers and develops antibody-based drugs for the treatment of inflammatory diseases, immune-related disorders and cancer. The company develops pipeline products using its proprietary mAb generating platform, DiversityTrap and ka …
  • Korea Petrochemical Ind. Co Ltd (006650):企業の財務・戦略的SWOT分析
    Summary Korea Petrochemical Ind. Co Ltd (KPICL) is a chemical company that manufactures and markets petrochemical products. The company provides products such as olefins, aromatics, polypropylene, EO and EG, PP and HDPE. It provides olefins products such as ethylene, propylene, butene, butane, isobu …
  • Cox Enterprises Inc:企業の戦略的SWOT分析
    Cox Enterprises Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and se …
  • M.M.Warburg & Co Kgaa:企業の戦略・SWOT・財務分析
    M.M.Warburg & Co Kgaa - Strategy, SWOT and Corporate Finance Report Summary M.M.Warburg & Co Kgaa - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerin …
  • Exxon Mobil Corp Oil & Gas Exploration and Production Operations and Cost Analysis – Q4, 2017
    Exxon Mobil Corp Oil & Gas Exploration and Production Operations and Cost Analysis - Q4, 2017 Summary Exxon Mobil Corp (ExxonMobil) is an integrated oil and gas company that explores for and produces crude oil and natural gas; manufactures petroleum products; transports and sells crude oil and petro …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆